Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma

Wild-type p53 tumor suppressor activity in neuroblastoma tumors is hampered by increased MDM2 activity, making selective MDM2 antagonists an attractive therapeutic strategy for this childhood malignancy. Since monotherapy in cancer is generally not providing long-lasting clinical responses, we here...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncotarget
Asıl Yazarlar: Van Goethem, Alan, Yigit, Nurten, Moreno-Smith, Myrthala, Vasudevan, Sanjeev A., Barbieri, Eveline, Speleman, Frank, Shohet, Jason, Vandesompele, Jo, Van Maerken, Tom
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Impact Journals LLC 2017
Konular:
Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5593624/
https://ncbi.nlm.nih.gov/pubmed/28915653
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18982
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller